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Abstract: The underlying factors contributing to metatarsophalangeal joint deformity, a known
precursor to skin breakdown in individuals with diabetes mellitus (DM), is likely to involve
multiple body systems. The purpose of this cross-sectional study was to identify multi-system
factors associated with metatarsophalangeal joint deformity in individuals with type 2 DM and
peripheral neuropathy (n = 60). Metatarsophalangeal joint deformity was quantified with a computed
tomography (CT) scan. System biomarkers included the musculoskeletal system (foot intrinsic
muscle deterioration, tarsal/metatarsal bone mineral density, ankle dorsiflexion, metatarsophalangeal
extension movement during a sit to stand task); the vascular system (ankle-brachial index); and
the endocrine/immune systems (high sensitivity C-reactive protein, skin intrinsic fluorescence, and
hemoglobin A1C). Muscle deterioration (r = 0.27), bone density (r = −0.35), metatarsophalangeal
extension movement (r = 0.50), maximum dorsiflexion (r = −0.31), and ankle-brachial index
(r = 0.33) were related to metatarsophalangeal joint deformity (p < 0.05). Bone mineral density and
metatarsophalangeal extension movement were retained in a regression model relating to deformity
(R2 = 0.34). All musculoskeletal system biomarkers and the ankle-brachial index demonstrated
weak to moderate relationships to metatarsophalangeal joint deformity. Bone mineral density of
the tarsal/metatarsal bones and extending the toes during a sit to stand task were the two strongest
factors associated with metatarsophalangeal joint deformity. Evaluation and management of foot
bone mineral density and toe extension movement pattern could reduce metatarsophalangeal joint
deformity and the risk of skin breakdown and subsequent amputation.
Keywords: imaging; computed tomography; magnetic resonance imaging; perfusion; bone mineral
density; intramuscular fat; advanced glycation end-products; hammer toe; claw toe; C-reactive protein

1. Introduction
Diabetes mellitus (DM)-related foot complications present a substantial economic and social
burden [1,2] and negatively impact individuals’ quality of life [3,4] and medical outcomes [5].
Peripheral neuropathy and metatarsophalangeal (MTP) joint hyperextension deformity are common
DM-related complications that increase the risk of ulceration and amputation [6,7]. MTP joint
hyperextension deformity is associated with both “claw toe” and “hammertoe” deformities, depending
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on the resulting flexion or extension of the interphalangeal joint. However, the area of high pressure
at risk for skin breakdown is at the metatarsal head due to MTP joint hyperextension deformity,
irrespective of the interphalangeal joint position. Early detection and care of foot-related complications
have the potential to minimize progression and negative consequences on patients’ health and quality
of life.
Diabetes is a systemic disease and MTP joint deformity is likely to be a focal manifestation
of multi-system deterioration [8,9]. Neural and motor dysfunction contribute to deficits in muscle
strength [10–12], fatty infiltration of intrinsic foot muscle [13–15], and altered movements during
functional tasks that have been correlated to MTP joint hyperextension [16]. In addition to neural and
motor dysfunction, the vascular system has a number of DM-related impairments including peripheral
artery disease, endothelial dysfunction [17], and blood flow dysregulation from autonomic nervous
system dysfunction [18]. Both the large and small vessels of the foot are affected, impairing muscle
performance and bone mineral density [8,9,19].
Compounding neural, motor, and vascular dysfunction, chronic hyperglycemia contributes to the
accumulation of advanced glycation end-products (AGEs). AGEs accumulation promotes soft tissue
dysfunction and is associated with limited ankle joint mobility [14], which is thought to increase stress
to the forefoot and MTP joints during weightbearing activities. Furthermore, as AGEs bind with their
receptor, inflammatory pathways are upregulated, promoting a pro-inflammatory environment [20]
and exacerbating cellular and tissue stress.
Impaired function of these systems is likely to occur simultaneously [8]. There is growing evidence
pointing at interactions within and between systems and their role in diabetic neuropathic foot
deformity. Loss of intrinsic foot muscles [13–15,21–23] has been associated with deformities in the
MTP joint [13,14,22] and midfoot [15]. Foot health and amputation risk have also been found to relate
to cardiovascular [24,25] and inflammatory [24] markers. For the healthcare provider, the complex
interaction of body systems influencing foot health in individuals with DM and peripheral neuropathy
underscores the importance of a comprehensive systems assessment [26]. However, there is limited
literature characterizing the diabetic neuropathic foot across multiple body systems.
Previous research has identified independent relationships between MTP joint deformity and
musculoskeletal factors (toe extension movement during sit to stand [16] and intrinsic foot muscle
deterioration [13,14,22]). Study design limitations have prevented the examination of the contribution
of key measures across multiple body systems hypothesized to contribute to MTP joint deformity.
Therefore, the purpose of this study was to take a multi-system approach to contributors to MTP
joint deformity, using a comprehensive set of clinical measures. We hypothesized that biomarkers
from musculoskeletal, vascular, and endocrine/immune systems would relate to MTP joint deformity;
however, we anticipated that musculoskeletal factors would bear the strongest relationship to foot
deformity given that the outcome of interest is bone alignment.
2. Experimental Section
This is a cross-sectional analysis of individuals with type 2 DM and diabetic peripheral neuropathy
from the baseline time point of an ongoing longitudinal study (ClinicalTrials.gov: NCT02616263).
All data collection occurred in laboratory and clinical radiology areas at Washington University School
of Medicine in St. Louis between 2016 and 2018. This study was approved by the Washington University
Medical School in St. Louis, Institutional Review Board.
The presence of peripheral neuropathy was defined as an inability to sense a 5.07 Semmes-Weinstein
monofilament on at least one of six locations on the plantar foot, a vibration perception threshold on
the plantar aspect of the great toe greater than 25V [27], or an examination score on the Michigan
Neuropathy Screening Instrument [28] greater than 2. Participants were excluded if they had peripheral
neuropathy with a causal factor other than DM, severe arterial disease (ankle-brachial index (ABI) < 0.9
or > 1.3) [29,30], lower-extremity amputation involving multiple toes, acute shoulder injury (required
for the aims of the longitudinal study but not relevant for this analysis), pregnancy, weight greater
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than 180 kg (exceeding magnetic resonance imaging (MRI) scanner weight limitations), presence of a
neuropathic ulcer, or age greater than 75.
To limit bias, the individuals responsible for post-processing and measurement of data were not
the same individuals as those conducting the clinical examination.
2.1. Participant Characteristics
Of participants assessed for eligibility (n = 271), 200 did not meet inclusion criteria and 11 declined
participation, resulting in 60 participants included in the study. Age, sex, body mass index, DM
duration, and self-reported function per the Foot and Ankle Ability Measure (FAAM) [31] were
obtained for descriptive purposes (Table 1).
Table 1. Participant Demographics.

1

Characteristic

Value 1

Sex (male, female)
Age (years)
Body mass index (kg/m2 )
Diabetes duration (years)
Hemoglobin A1C (%)
Michigan Neuropathy Score
Foot and Ankle Ability Measure Score

26, 34
67 (6)
35 (7)
19 (18)
7.1 (1.3)
5 (1)
80 (20)

Values are mean (standard deviation, SD) unless otherwise noted.

2.2. MTP Joint Deformity Assessment
A volumetric quantitative computed tomography (CT) scan of the foot was obtained (Siemens
Biograph 40 CT, Siemens Medical Systems, Inc., Iselin, NJ, USA). The participant was positioned supine
with the ankle in 30◦ of plantarflexion. Scan parameters were 40 images per rotation, 370 millisecond
rotation time, 24 mm collimation, 0.6 mm slice thickness, 220 mAs, 120 kVp. A CT calibration phantom
(Mindways, Austin, TX, USA; Calibration value: L11G 11F1 1171 611L) was placed in front of the foot.
Second MTP joint angle was measured as the angle formed by the long axis of the second metatarsal
and the long axis of the second proximal phalanx. Error associated with angular measures of the foot
using CT has been previously reported [32]. The supplement (180◦ -angle) of the angle is reported, with
a larger angle representing greater deformity [8,14].
2.3. Musculoskeletal System Assessment
Foot intrinsic muscle deterioration ratio was measured via MRI (Siemens Prisma Fit 3T, Siemens
Medical Systems, Malvern, PA, USA) similar to those previously described [14,15,33,34]. The participant
was placed supine with the extremity coil around the foot. The MRI sequence parameters were: single-shot,
Dixon acquisition (Turbo Spin Echo, (TSE 2D), repetition time/echo time (TR/TE) = 1190 msec/13 msec;
flip angle = 123 degrees; Field of View (FOV) = 129 × 114 mm; matrix = 512 × 576; slice thickness =
3.5 mm; pixel spacing = 0.2246 × 0.2246 mm; number of averages = 1; acquisition time was 10–13 min.
Muscle and fat volumes were segmented and estimated using previously described reliable and valid
measures [33]. Muscle deterioration ratio was defined as the inter/intramuscular adipose tissue volume
divided by muscle volume.
Bone mineral density (BMD) of each tarsal and metatarsal bone was quantified as previously
described using CT [35,36]. Each tarsal and metatarsal bone was segmented. The Hounsfield unit value
for each bone was determined and converted to BMD using the calibration phantom. The mean of all
12 tarsal and metatarsal bones was used for analysis.
Ankle dorsiflexion was assessed using CT. Participants were asked to actively dorsiflex their ankle
as much as possible, holding the position for the scan (up to 10 s). The ankle dorsiflexion angle was
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measured from the intersection of one line drawn from the bottom of the second metatarsal head to the
bottom of the posterior calcaneus and a second line drawn down the middle of the tibia.
Second MTP extension movement during a sit to stand activity was assessed using a 10 camera,
3D motion capture system (Vicon MX, Los Angeles, CA, USA) and modified-Oxford marker set [37,38].
Participants were asked to stand from a seated position in an armless chair without using their arms.
Motion capture data was smoothed and MTP extension movement was measured using Visual3D
(C-Motion Inc., Germantown, MD, USA) software. To measure MTP extension movement, the angle
between second proximal phalanx and the second metatarsal segments was measured at peak extension
and static standing. The difference between these two angles was considered the joint extension
excursion. Three trials were averaged for analysis.
2.4. Vascular System Assessment
Ankle-brachial index (ABI) was calculated as the systolic blood pressure of the tibial artery divided
by the systolic blood pressure of the brachial artery. The toe-brachial index (TBI) was determined as
the first dorsal interosseous artery systolic blood pressure over the brachial systolic blood pressure.
2.5. Endocrine and Immune Systems Assessment
High sensitivity C-reactive Protein (hsCRP), a marker of inflammation, and hemoglobin A1C
(HbA1C), a marker of glycemic control, were assessed via blood draw. Accumulation of AGEs was
assessed via skin intrinsic fluorescence using a SCOUT DS (VeraLight, Albuquerque, NM, USA) skin
fluorescence spectrometer [39]. Two measurements were taken from the volar aspect of the left forearm.
Skin intrinsic fluorescence was excited with a light emitting diode centered at 375 nm, detected over an
emission range of 375–600 nm, and is reported in arbitrary units (AU).
2.6. Statistical Analysis
Descriptive statistics are reported. The strength of relationship between important system
measures and MTP joint deformity was examined with a Pearson correlation matrix. The variables
with a significant Pearson correlation to MTP joint deformity and potential confounding demographic
characteristics (age, sex, and body mass index) were considered in a multivariate linear regression
analysis to quantify the association between all body system biomarkers and foot deformity.
Backward model selection was used to determine which variables to retain. Regression diagnostics
were used to check the assumptions of linear regression and model fit. All the statistical tests were
two-sided at significance level 0.05 and analyses were performed with SAS 9.4 (SAS Inc, Cary, NC,
USA). Missing data were not adjusted for in the analysis, and total n is reported for each variable.
3. Results
Descriptive statistics for body system biomarkers are listed in Table 2.
Table 2. Descriptive statistics for primary and secondary outcomes.
Outcome

n

Mean (SD) 1

2nd MTP joint angle (degrees)
Muscle deterioration ratio
Bone mineral density–mean of all tarsal, metatarsal bones (HU) 3
MTP extension movement with sit to stand (degrees)
Maximum dorsiflexion (degrees)
Ankle-brachial index
Toe-brachial index
High sensitivity C-reactive protein (mg/L)
Hemoglobin A1C (%)
Skin intrinsic fluorescence (AU) 4

60
58
60
59
60
57
58
56
59
54

53.0 (12.8)
0.32 (0.18)
418 (58)
16 (10)
97.7 (8.1)
1.11 (0.13)
1.12 (0.13)
3.5 (3.1)
7.1 (1.3)
2.96 (0.69)

2

1

standard deviation (SD); 2 Metatarsophalangeal (MTP); 3 Hounsfield units (HU); 4 Arbitrary units (AU).
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Correlations between variables are shown in Table 3. Statistically significant correlations were
detected between second MTP joint angle and MTP joint extension during sit to stand, maximum ankle
dorsiflexion, BMD, ABI, and muscle deterioration ratio. The relationship between second MTP joint
angle and skin intrinsic fluorescence neared statistical significance (p = 0.05).
Table 3. Pearson correlation matrix for primary variables of interest.1

MDR 2
BMD 3
MTP extension movement 4
Maximum dorsiflexion
ABI 5
SIF 6
HbA1C 7
hsCRP 8

2nd MTP
Joint Angle

MDR

BMD

MTP Extension
Movement

Maximum
Dorsiflexion

ABI

SIF

HbA1C

0.273 *
−0.352 **
0.504 **
−0.311 **
0.329 *
−0.268
−0.124
−0.005

—
−0.138
0.310 *
−0.243
0.123
−0.062
−0.102
−0.049

—
—
−0.179
0.246
−0.067
0.014
0.131
0.191

—
—
—
−0.284 *
0.138
−0.355
−0.150
−0.097

—
—
—
—
0.068
0.051
−0.033
−0.102

—
—
—
—
—
−0.163
0.059
−0.182

—
—
—
—
—
—
−0.078
0.379 **

—
—
—
—
—
—
—
0.129

1 p < 0.05 (*), p < 0.01 (**); 2 muscle deterioration ratio (MDR); 3 bone mineral density (BMD); 4 metatarsophalangeal
(MTP); 5 ankle-brachial index (ABI); 6 skin intrinsic fluorescence (SIF); 7 hemoglobin A1C (HbA1C); 8 high sensitivity
C-reactive protein (hsCRP).

Muscle deterioration ratio, BMD, MTP joint extension during sit to stand, maximum ankle
dorsiflexion, ABI, skin intrinsic fluorescence, age, BMI, and sex were considered in a multivariate linear
regression analysis to further investigate associations with second MTP joint angle. Of these variables,
BMD (slope= −0.061, p = 0.009) and MTP joint extension movement during sit to stand (slope = 0.560,
p < 0.001) were retained in the model. These two variables explained 34% of variation in second MTP
joint angle (R2 = 0.34) (Figure 1).
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4. Discussion
This study characterized relationships between MTP joint deformity and multi-system
biomarkers in people with DM. These relationships suggest potential mechanisms underlying MTP
joint deformity and future treatment targets. Lower BMD and greater amounts of MTP extension
movement during the sit to stand task were the strongest factors associated with MTP joint deformity
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4. Discussion
This study characterized relationships between MTP joint deformity and multi-system biomarkers
in people with DM. These relationships suggest potential mechanisms underlying MTP joint deformity
and future treatment targets. Lower BMD and greater amounts of MTP extension movement during
the sit to stand task were the strongest factors associated with MTP joint deformity in this group of
individuals. However, poor foot intrinsic muscle quality, impaired ankle dorsiflexion range of motion,
and greater ABI also demonstrated weak to moderate relationships to greater MTP joint deformity.
Musculoskeletal factors bear the strongest relationship to bony MTP joint deformity, but the findings
of this study also support the contribution of the vascular system to foot health. Contributions from
multiple body systems underscore the importance of a comprehensive clinical assessment in providing
foot care to individuals with DM.
To our knowledge, this study is the first to link lower BMD with MTP joint hyperextension
deformity. The importance of BMD has been established in individuals with DM and severe foot
deformity, specifically Charcot neuropathic osteoarthropathy [40]. While the individuals included in
this study had generally well-preserved muscle quality on MRI and good self-reported foot function
per the FAAM (Tables 1 and 2), on average this group demonstrated a 12% deficit in BMD compared
to individuals without DM previously reported using the same CT technique [35]. The relationship
of BMD and MTP joint deformity found in the present study is in contrast to a prior study reporting
no relationship between MTP joint deformity and metatarsal head or shaft BMD [7]. It may be that
isolated BMD changes close to the joint line are also influenced by arthritic or cortical bone changes that
do not represent overall bone health in the foot as well as the mean BMD of all tarsal and metatarsal
bones. Interventions aimed at improving BMD through modifying physical activity or medical means
may be helpful in slowing the progression of MTP joint deformity, and should be considered in future,
longitudinal studies.
The relationship between movement pattern and deformity underscores the importance of
assessing the diabetic foot in a resting position and with movement. It has been reported that extension
of the MTP joints during functional movements, such as walking and moving between sitting and
standing, relates to severity of second MTP joint deformity [16]. The results of this study show a
similar magnitude of relationship between MTP extension movement while moving sit to stand and
severity of second MTP joint deformity. We also observed a relationship between foot intrinsic muscle
quality and MTP extension movement pattern. This pattern is similar to what is observed with intrinsic
wasting in the hand. As the intrinsic muscles atrophy and finger flexor muscles adaptively shorten,
there is a tendency toward clawing of the fingers [41]. It seems that the foot may follow a similar
pattern in which the lower leg musculature is recruited in anticipation of standing, but the foot intrinsic
muscles are unable to counterbalance the pull of the toe extensors and shortening of the toe flexors.
Over time, it is reasonable to speculate that abnormalities in alignment and aberrant movement patterns
could advance deformity and potential for ulceration at the metatarsal heads or on the toes [13,14,16].
Future studies investigating the correction of aberrant movement patterns may help to determine
whether or not interventions aimed at correcting these movement patterns can slow the progression of
MTP joint deformity.
Diabetic peripheral neuropathy has been consistently associated with lower foot intrinsic muscle
volume [21,22] and poor muscle quality [13–15]. Prior studies using quantitative measures of foot
intrinsic muscle quality have identified moderate, statistically significant relationships between intrinsic
muscle quality and 2nd MTJ angle [13,14]. Cheuy et al. [13] reported a possible threshold effect as
the magnitude of association between muscle deterioration and second MTP joint angle increased
with muscle deterioration ratios greater than 1.0. Similar to prior studies [13,14], we observed a
weak, statistically significant relationship between foot intrinsic muscle quality and second MTP
joint angle in the present study (r = 0.27). Muscle deterioration ratio (volume of intramuscular
fat/muscle) was similar to healthy participants reported previously using similar methods [13,15] and
lower than values previously published in individuals with DM and peripheral neuropathy [13,15],
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indicating well-preserved muscle quality in the individuals included in the present study. The relatively
well-maintained muscle quality in the group of individuals included in the present study may have
limited the magnitude of this relationship.
Vascular dysfunction has been inconsistently linked to alterations in BMD [19], though we did
not see a similar relationship in this study. To our knowledge, however, this is the first study to
report a relationship between macro-vasculature and MTP joint deformity. Specifically, in this group
of individuals with a range of what could be considered normal ABI values [29,30], we found that
individuals with higher ABI, an indicator of calcific arterial disease, had greater MTP joint deformity.
It is important to note that, while the cutoff used in this study is supported by the American Diabetes
Association for the diagnosis of peripheral arterial disease in people with DM [30], there is not a
universally agreed upon cutoff for normal ABI [42], so individuals included in our study could have
underlying calcific disease. Further, vascular dysfunction in people with DM is associated with presence
of peripheral neuropathy [43]. Given that all of the participants in this study were considered to have
peripheral neuropathy of varying severities, it is possible that the factors observed to be associated
with changes in MTP joint deformity are moderated by peripheral neuropathy.
We did not observe any statistically significant relationships between MTP joint deformity and
biomarkers assessing the endocrine and immune systems. It may be that MTP joint deformity is a
process that takes a long time (months to several years) whereas the biomarkers included in this study
capture function of these systems over a fairly short duration (up to several months). We did identify
a moderate relationship between skin intrinsic fluorescence—a measure of AGEs accumulation in
the skin – and hsCRP – a measure of inflammation. Both AGEs and C-reactive protein are known to
upregulate inflammatory pathways, including the NF-kappaB pathway [20,44]. Relationships between
AGEs in the blood and C-reactive protein have been reported in individuals with DM [45,46], but to
our knowledge the present study is the first to report this relationship using AGEs assessed via skin
intrinsic fluorescence.
This is a cross-sectional study designed to investigate relationships between factors, so change in
these factors over time with disease progression is speculative. Restrictive inclusion criteria for ABI and
functional limitations resulted in limited variability of these parameters within the group of individuals
studied. Individuals with severe deformity, ulceration, functional limitations, and peripheral vascular
disease were excluded, so the findings of this study should not be extrapolated to these individuals.
The group of individuals included in this study on average had well-controlled, type 2 DM with
comorbid obesity. Fifty-seven percent of the group were female. These characteristics are important to
consider when extrapolating these findings to other patient groups. The CT dorsiflexion measure used
is limited since it is an active range of motion measure and could be impacted by participant strength.
However, the CT measure has the advantage of visualizing landmarks rather than relying on palpated
landmarks, as would be the case with passive range of motion with a goniometer.
From a clinical standpoint, the results of this study provide a potential focus for assessment
and interventions for the diabetic foot, though these suggestions should be further investigated in
longitudinal studies. This study supports the need for a comprehensive systems assessment. In the case
of MTP joint deformity, the local, musculoskeletal system had the strongest association with deformity,
but vascular dysfunction may also be a factor to consider with MTP joint deformity. Focusing an
examination solely on a single system could exclude potentially important treatment targets or
comorbid considerations. Concerning interventions, an exercise program to increase dorsiflexion range
of motion, improve performance of the foot intrinsic muscles, and minimize MTP joint excursions
during functional activities may help to slow or even reverse the progression of MTP joint deformity.
Despite the challenging nature of managing this chronic problem, there is growing evidence and interest
in activity and exercise interventions that have a positive effect on diabetic foot related outcomes [47–50].
Additional longitudinal studies are required to identify whether or not intervening on these factors
would restore or slow joint deformity.
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5. Conclusions
Biomarkers of the musculoskeletal and vascular systems relate to second MTP joint angle, a
measure of forefoot deformity. Bone mineral density and the tendency to extend the MTP joints during
typical movements had the strongest association with MTP joint deformity. These results help inform
evaluation and management of multi-system factors contributing to this risk factor for skin breakdown
and subsequent amputation.
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